{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:41Z","timestamp":1772177501897,"version":"3.50.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>First-generation somatostatin receptor ligands (SRLs) mainly target SSTR2, whereas neuroendocrine tumors (NETs) often express multiple SSTR subtypes, frequently SSTR5. Dual SSTR2\/SSTR5 targeting may enhance anti-hormonal and antiproliferative effects. We evaluated five novel dual SSTR2\/SSTR5 agonists (SMTR-001 to SMTR-005) in preclinical NET models to assess their anti-secretory and anti-proliferative effects in representative preclinical NET models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The human insulinoma-derived NT-3 cell line and the murine AtT-20 corticotroph cell line, both expressing SSTR2 and SSTR5, were treated with 1\u201350 nM of the novel SRLs or reference agents (octreotide, pasireotide). Insulin and ACTH secretion were quantified by ELISA and cell viability was measured after 72 h (AtT-20) or 5 days (NT-3). A putative lead compound, SMTR-002, was further tested in 3D spheroid cultures of NT-3 cells. Intracellular cAMP modulation was evaluated after forskolin stimulation in AtT-20 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In NT-3 cells, all dual SRLs inhibited insulin secretion (\u221265% to \u221295%), with SMTR-002, SMTR-004, and SMTR-005 showing significantly greater inhibition than octreotide at 10 nM. Each compound also reduced cell proliferation (\u221230% to \u221244%). In 3D cultures of NT-3 cells, SMTR-002 reduced insulin secretion to a degree comparable to octreotide but, unlike octreotide, significantly decreased cell proliferation. In AtT-20 cells, four novel SRLs significantly reduced ACTH secretion (-11% to -69%), with SMTR-001 and SMTR-004 showing efficacy comparable to pasireotide. SMTR-002 and SMTR-003 demonstrated the greatest antiproliferative effects (\u221253% and \u221248% at 10 nM). In AtT-20 cells, SMTR-002 also suppressed forskolin-induced cAMP accumulation more strongly than reference SRLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dual SSTR2\/SSTR5 agonists exhibit antisecretory and antiproliferative activity in NET models that was similar or even superior to reference SRLs. These findings support their further development as next-generation SRLs for SSTR2\/5-expressing tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1766563","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:05Z","timestamp":1772169905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models"],"prefix":"10.3389","volume":"16","author":[{"given":"Francesco","family":"Fedeli","sequence":"first","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia","place":["Pavia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Bistika","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia","place":["Pavia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ascione","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia","place":["Pavia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Marangelo","sequence":"additional","affiliation":[{"name":"Institute for Diabetes and Cancer, Helmholtz Munich","place":["Neuherberg, Germany"]},{"name":"Joint Heidelberg-Institute for Diabetes and Cancer (IDC) Translational Diabetes Program, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio L.","family":"Guzzi","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia","place":["Pavia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Schrader","sequence":"additional","affiliation":[{"name":"I. Department of Medicine, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan G.","family":"Harris","sequence":"additional","affiliation":[{"name":"Holman Division of Diabetes Endocrinology & Metabolism, New York University (NYU) Langone Medical Center, Grossman School of Medicine, New York University","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia S.","family":"Pellegata","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia","place":["Pavia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203323","article-title":"Dethroning of neuroendocrine tumor as an orphan disease: US incidence, prevalence, and survival in the 21st century","volume":"17","author":"Yu","year":"2025","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2515798","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000167739.56948.a9","article-title":"Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment","volume":"17","author":"Oberg","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41698-025-00938-1","article-title":"Emerging innovations in theranostics for pancreatic neuroendocrine tumors","volume":"9","author":"Karimi","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010436","article-title":"Somatostatin and somatostatin receptors in tumour biology","volume":"25","author":"Kumar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e230298","DOI":"10.1530\/JOE-23-0298","article-title":"Somatostatin receptors and the associated intracellular machinery: the two sides of the coin","volume":"260","author":"Campana","year":"2024","journal-title":"J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/endrev\/bnae022","article-title":"Structure and function of somatostatin and its receptors in endocrinology","volume":"46","author":"Zhang","year":"2025","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-1404-x","article-title":"The role of somatostatin analogs in Cushing's disease","volume":"7","author":"van der Hoek","year":"2004","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e220296","DOI":"10.1530\/EC-22-0296","article-title":"Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"11","author":"Wolf","year":"2022","journal-title":"Endocr Connect."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00007","article-title":"Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives","volume":"5","author":"Baldelli","year":"2014","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0010","article-title":"Pasireotide in the treatment of neuroendocrine tumors: a review of the literature","volume":"25","author":"Vitale","year":"2018","journal-title":"Endocr Relat Cancer."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2024.101608","article-title":"Medical treatment of acromegaly - When the tumor size matters: A narrative review","volume":"78","author":"Doknic","year":"2024","journal-title":"Growth Horm IGF Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-19","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017741073","article-title":"Somatostatin analogs: is one better than other","volume":"9","author":"Berardi","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40618-023-02170-9","article-title":"Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story","volume":"47","author":"Faggiano","year":"2024","journal-title":"J Endocrinol Invest."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac574","article-title":"Peptide receptor radionuclide therapy","volume":"107","author":"Hofland","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog 177Lu-DOTA0, Tyr3 octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223632","article-title":"Emerging diagnostics and therapies in neuroendocrine neoplasms: A critical review","volume":"17","author":"Hernandez-Felix","year":"2025","journal-title":"Cancers (Basel)."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.48.7.1184","article-title":"Hormone-producing cultures of adrenal and pituitary tumor origin","volume":"48","author":"Buonassisi","year":"1962","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705235","article-title":"Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs","volume":"139","author":"Cervia","year":"2003","journal-title":"Br J Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/1541-7786.MCR-17-0163","article-title":"Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model","volume":"16","author":"Benten","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000543136","article-title":"The novel SSTR3 full agonist ITF2984 shows antitumor properties against pancreatic neuroendocrine tumors","volume":"115","author":"Bistika","year":"2025","journal-title":"Neuroendocrinology"},{"key":"B35","volume-title":"Design and synthesis of peptidomimetic building blocks and bioactive molecules","author":"Li","year":"1998"},{"key":"B36","article-title":"Computational and NMR studies of biologically active molecules","author":"Jiang","year":"1998","journal-title":"San Diego CA: Univ California San Diego"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1311","article-title":"Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy","volume":"94","author":"Ben-Shlomo","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2016.11.002","article-title":"3D tumor spheroids: an overview on the tools and techniques used for their analysis","volume":"34","author":"Costa","year":"2016","journal-title":"Biotechnol Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26845","article-title":"3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs","volume":"116","author":"Nunes","year":"2019","journal-title":"Biotechnol Bioeng."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010190","article-title":"3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs","volume":"14","author":"Barbosa","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119225","article-title":"Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation","volume":"99","author":"Shimon","year":"1997","journal-title":"J Clin Invest."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas","volume":"100","author":"Shimon","year":"1997","journal-title":"Novel potential Ther Funct pituitary tumors. J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.1.7099","article-title":"BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas","volume":"86","author":"Saveanu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030303","article-title":"Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion","volume":"88","author":"Ren","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.892668","article-title":"Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation","volume":"13","author":"Treppiedi","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.regpep.2009.08.011","article-title":"The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5","volume":"159","author":"Grant","year":"2010","journal-title":"Regul Pept"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2009.11.006","article-title":"Regulation of prostate cancer cell proliferation by somatostatin receptor activation","volume":"315","author":"Ruscica","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.10.027","article-title":"Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth","volume":"382","author":"Ruscica","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/me.2007-0334","article-title":"Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization","volume":"22","author":"Grant","year":"2008","journal-title":"Mol Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"\u00d6berg","year":"2004","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol."},{"key":"B52","article-title":"Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists","volume":"47","author":"Cescato","year":"2006","journal-title":"J Nucl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the \u03b22-adrenergic receptor-Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2013.11.003","article-title":"Somatostatin analogs: does pharmacology impact antitumor efficacy","volume":"25","author":"Chalabi","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"New Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Design Dev Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx078","article-title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"28","author":"Kulke","year":"2017","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e099996","DOI":"10.1136\/bmjopen-2025-099996","article-title":"Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomized controlled trial protocol","volume":"15","author":"Chhajlani","year":"2025","journal-title":"BMJ Open"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071394","article-title":"Comprehensive assessment of somatostatin receptors in various neoplasms: A systematic review","volume":"14","author":"Priyadarshini","year":"2022","journal-title":"Pharmaceutics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"K6","DOI":"10.1093\/ejendo\/lvae170","article-title":"Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone-secreting pituitary tumors","volume":"192","author":"Campana","year":"2025","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:06Z","timestamp":1772169906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":61,"alternative-id":["10.3389\/fonc.2026.1766563"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1766563","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1766563"}}